drugset / Trial / NCT00901511

Inhaled GM-CSF Therapy of Autoimmune PAP

NCT00901511 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomized, open-label, long-term, phase 2 study of inhaled granulocyte/macrophage-colony stimulating factor following whole lung lavage therapy in patients with autoimmune pulmonary alveolar proteinosis.

Timeline

Start
2009-07
Primary completion
2016-06
Completion
2016-06

Outcome

Met primary endpoint

registry analysis (superiority test); Control Group vs GM-CSF Group; p = 0.0078; Median Difference (Final Values) 12; Wilcoxon (Mann-Whitney) NCT00901511 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject sargramostim Protein / enzyme biologic 250 ug Inhaled